It is a novel platelet inhibitor for acute coronary syndromes planned for percutaneous coronary intervention (PCI).
The recommended dose of prasugrel is a 60mg oral loading dose followed by a maintenance dose of 10mg orally daily, which should be administered with concomitant aspirin 75-325mg orally daily. For patients weighing
Active pathological bleeding (peptic ulcer or ICH) previous (TIA) or stroke. Anticipated coronary artery bypass graft (CABG) surgery within 7 days. Age of >75yrs, unless patient is deemed at high risk of recurrent ischemic events (diabetes DM or prior MI). Recent fibrinolytic therapy. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors other than daily aspirin, warfarin therapy, Anti-platelet therapy, severe hepatic impairment.
Prasugrel should be discontinued for active bleeding, elective surgery, TIA or stroke. Interruption or premature discontinuation of anti-platelet medications has been associated with an increased risk of stent thrombosis, Ml, and death. Advanced age (>75yrs), Low body weight (
Bruising, Headache Disorder, Hyperlipidemia, Hypertension, Anemia, Atrial Fibrillation, Back pain, Bradycardia, chest pain, cough, diarrhea, dizziness, dyspnea, fatigue, gastrointestinal hemorrhage, hemorrhage, hypotension, nausea, pain, peripheral edema, abnormal hepatic function tests, angioedema, epistaxis, fever, hematoma, hypersensitivity drug reactions, intracranial bleeding, leukopenia, retinal hemorrhage, thrombocytopenic disorder, thrombotic thrombocytopenic purpura.
Aspirin, fiber therapy, fish oil (omega-3 polyunsaturated fatty acids) furosemide, Atorvastatin, Lisinopril, Loratadine, Metoprolol, nitroglycerin, Levothyroxine, Ubiquinone, Isosorbide mononitrate.
|Brand Name||Manufactured by|
|APAGREL||INTAS PHARMACEUTICALS LTD.|
|DEKLOT||GROWNBURY PHARMACEUTI-CALS PVT. LTD|
|EFIPLAT||Sun Pharmaceutical Industries Ltd.|
|PASUGEN||UNICHEM LABORATORIES LTD.|
|PRAIL||ANT PHARMACEUTICALS PRIVATE LIMITED|
|PRAX||TORRENT LABS (P) LTD.|